Hesitancy Toward a COVID-19 Vaccine.


Journal

EcoHealth
ISSN: 1612-9210
Titre abrégé: Ecohealth
Pays: United States
ID NLM: 101222144

Informations de publication

Date de publication:
03 2021
Historique:
received: 10 07 2020
accepted: 11 03 2021
revised: 11 03 2021
pubmed: 5 6 2021
medline: 2 9 2021
entrez: 4 6 2021
Statut: ppublish

Résumé

The scientific community has come together in a mass mobilization to combat the public health risks of COVID-19, including efforts to develop a vaccine. However, the success of any vaccine depends on the share of the population that gets vaccinated. We designed a survey experiment in which a nationally representative sample of 3,133 adults in the USA stated their intentions to vaccinate themselves and their children for COVID-19. The factors that we varied across treatments were: the stated severity and infectiousness of COVID-19 and the stated source of the risk information (White House or the Centers for Disease Control). We find that 20% of people in the USA intend to decline the vaccine. We find no statistically significant effect on vaccine intentions from the severity of COVID-19. In contrast, we find that the degree of infectiousness of the coronavirus influences vaccine intentions and that inconsistent risk messages from public health experts and elected officials may reduce vaccine uptake. However, the most important determinants of COVID-19 vaccine hesitancy seem to be distrust of the vaccine safety (including uncertainty due to vaccine novelty), as well as general vaccine avoidance, as implied by not having had a flu shot in the last two years.

Identifiants

pubmed: 34086129
doi: 10.1007/s10393-021-01524-0
pii: 10.1007/s10393-021-01524-0
pmc: PMC8175934
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-60

Informations de copyright

© 2021. EcoHealth Alliance.

Références

J Med Internet Res. 2014 Feb 20;16(2):e60
pubmed: 24565696
PLoS One. 2013 Dec 11;8(12):e82131
pubmed: 24349200
PLoS One. 2018 Dec 7;13(12):e0208601
pubmed: 30532274
Vet J. 2007 Nov;174(3):472-80
pubmed: 17113798
Br Med Bull. 2000;56(1):110-20
pubmed: 10885109
Nature. 2020 Apr;580(7805):576-577
pubmed: 32346146
PLoS Med. 2018 Jun 12;15(6):e1002578
pubmed: 29894470
Lancet Infect Dis. 2019 Jul;19(7):684-686
pubmed: 31079949
Procedia Vaccinol. 2011;5:127-136
pubmed: 32288915
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
J Health Commun. 2014;19(1):67-81
pubmed: 24015878
J Clin Med. 2020 Feb 14;9(2):
pubmed: 32075152
Clin Infect Dis. 2011 Apr 1;52(7):911-6
pubmed: 21427399
Health Psychol. 2007 Mar;26(2):136-45
pubmed: 17385964
J Health Econ. 1998 Aug;17(4):475-97
pubmed: 10180927
JAMA. 2019 Apr 9;321(14):1344
pubmed: 30964534
Emerg Infect Dis. 2020 Jul;26(7):1470-1477
pubmed: 32255761
Vaccine. 2016 Jul 25;34(34):3972-8
pubmed: 27344291
Nature. 2011 May 26;473(7348):443-5
pubmed: 21614055
Risk Anal. 2001 Dec;21(6):1047-53
pubmed: 11824680
Lancet. 2018 Nov 24;392(10161):2244-2246
pubmed: 30496111
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
Risk Anal. 2000 Jun;20(3):353-62
pubmed: 10949414
Pediatrics. 2011 May;127 Suppl 1:S107-12
pubmed: 21502236
Risk Anal. 2016 Apr;36(4):831-46
pubmed: 26268067
Sci Rep. 2021 Oct 12;11(1):20222
pubmed: 34642341
PLoS One. 2021 Apr 21;16(4):e0249271
pubmed: 33882054
J Infect Dis. 2013 Mar 15;207(6):990-8
pubmed: 23264672
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
J Risk Uncertain. 2017;55(2):177-202
pubmed: 29497245
J Mark Access Health Policy. 2015 Aug 12;3:
pubmed: 27123187
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
Risk Anal. 1996 Aug;16(4):473-86
pubmed: 8819340
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052846
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Front Behav Neurosci. 2015 Nov 27;9:325
pubmed: 26640434
Risk Anal. 2002 Aug;22(4):713-23
pubmed: 12224745
Health Secur. 2017 Jan/Feb;15(1):28-30
pubmed: 28092446
Am J Epidemiol. 1986 Dec;124(6):1012-20
pubmed: 3096132
J Public Econ. 2021 Mar;195:104367
pubmed: 33531719

Auteurs

Linda Thunström (L)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA. lthunstr@uwyo.edu.

Madison Ashworth (M)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA.

David Finnoff (D)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA.

Stephen C Newbold (SC)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH